Alessio Annovazzi1, Virginia Ferraresi2,3, Sandra Rea4, Michelangelo Russillo2, Davide Renna2, Silvia Carpano5, Rosa Sciuto4. 1. Nuclear Medicine Unit, IRCCS - Regina Elena National Cancer Institute, Via Elio Chianesi, 53, 00144, Rome, Italy. alessio.annovazzi@ifo.gov.it. 2. First Division of Medical Oncology, IRCCS - Regina Elena National Cancer Institute, Rome, Italy. 3. Sarcomas and Rare Tumors Unit, IRCCS - Regina Elena National Cancer Institute, Rome, Italy. 4. Nuclear Medicine Unit, IRCCS - Regina Elena National Cancer Institute, Via Elio Chianesi, 53, 00144, Rome, Italy. 5. Second Division of Medical Oncology, IRCCS - Regina Elena National Cancer Institute, Rome, Italy.
Abstract
OBJECTIVES: Target therapy with BRAF/MEK inhibitors in metastatic melanoma is characterised by a high response rate; however, acquired resistance to treatment develops in many cases. We aimed to investigate if baseline total metabolic tumour volume (TMTV) and therapy-response assessment by [18F]FDG PET/CT have a prognostic role on progression-free survival (PFS) and overall survival (OS) in patients with metastatic melanoma receiving BRAF ± MEK inhibitors. METHODS: Fifty-seven patients who performed an [18F]FDG PET/CT at baseline and on treatment were retrospectively evaluated. A Cox proportional-hazard model was used to examine associations between OS and PFS with baseline clinical/PET parameters as well as for PET response. RESULTS: According to EORTC criteria, 34 patients were classified as responders (partial/complete metabolic response [PMR/CMR]) and 23 as non-responders (progressive/stable metabolic disease [PMD/SMD]). Baseline characteristics associated with a shorter PFS were more than two metastatic organ sites and TMTV > 56 cm3; the latter was the only independent feature at multivariate analysis. Patients achieving a CMR were associated with a prolonged PFS compared with those with PMR (median PFS 42.9 vs 8.8 months; p = 0.009). Disease progression occurred in new-onset disease sites in 87.5% of CMR, 7.1% of PMR and 34.8% of PMD/SMD (p < 0.001). High baseline TMTV and lack of treatment response were independent prognostic factors for OS, stratifying patients in three different prognostic classes (median OS 6.7, 18.3 and 102.2 months, respectively). CONCLUSIONS: Baseline TMTV and metabolic response may be useful prognostic indicators for PFS and OS in patients with advanced melanoma treated with BRAF/MEK inhibitors. KEY POINTS: • In a retrospective cohort of 57 metastatic melanoma patients treated with BRAF/MEK inhibitors, a TMTV > 56 cm3 at baseline [18F]FDG PET/CT was significantly correlated with a shorter PFS and OS. • The combined use of baseline TMTV along with PET response during treatment allowed for the identification of three groups of patients with very different median OS.
OBJECTIVES: Target therapy with BRAF/MEK inhibitors in metastatic melanoma is characterised by a high response rate; however, acquired resistance to treatment develops in many cases. We aimed to investigate if baseline total metabolic tumour volume (TMTV) and therapy-response assessment by [18F]FDG PET/CT have a prognostic role on progression-free survival (PFS) and overall survival (OS) in patients with metastatic melanoma receiving BRAF ± MEK inhibitors. METHODS: Fifty-seven patients who performed an [18F]FDG PET/CT at baseline and on treatment were retrospectively evaluated. A Cox proportional-hazard model was used to examine associations between OS and PFS with baseline clinical/PET parameters as well as for PET response. RESULTS: According to EORTC criteria, 34 patients were classified as responders (partial/complete metabolic response [PMR/CMR]) and 23 as non-responders (progressive/stable metabolic disease [PMD/SMD]). Baseline characteristics associated with a shorter PFS were more than two metastatic organ sites and TMTV > 56 cm3; the latter was the only independent feature at multivariate analysis. Patients achieving a CMR were associated with a prolonged PFS compared with those with PMR (median PFS 42.9 vs 8.8 months; p = 0.009). Disease progression occurred in new-onset disease sites in 87.5% of CMR, 7.1% of PMR and 34.8% of PMD/SMD (p < 0.001). High baseline TMTV and lack of treatment response were independent prognostic factors for OS, stratifying patients in three different prognostic classes (median OS 6.7, 18.3 and 102.2 months, respectively). CONCLUSIONS: Baseline TMTV and metabolic response may be useful prognostic indicators for PFS and OS in patients with advanced melanoma treated with BRAF/MEK inhibitors. KEY POINTS: • In a retrospective cohort of 57 metastatic melanoma patients treated with BRAF/MEK inhibitors, a TMTV > 56 cm3 at baseline [18F]FDG PET/CT was significantly correlated with a shorter PFS and OS. • The combined use of baseline TMTV along with PET response during treatment allowed for the identification of three groups of patients with very different median OS.
Authors: Nicholas Theodosakis; Matthew A Held; Alexander Marzuka-Alcala; Katrina M Meeth; Goran Micevic; Georgina V Long; Richard A Scolyer; David F Stern; Marcus W Bosenberg Journal: Mol Cancer Ther Date: 2015-05-06 Impact factor: 6.261
Authors: Selma Ugurel; Joachim Röhmel; Paolo A Ascierto; Jürgen C Becker; Keith T Flaherty; Jean J Grob; Axel Hauschild; James Larkin; Elisabeth Livingstone; Georgina V Long; Paul Lorigan; Grant A McArthur; Antoni Ribas; Caroline Robert; Lisa Zimmer; Dirk Schadendorf; Claus Garbe Journal: Eur J Cancer Date: 2020-03-13 Impact factor: 9.162
Authors: Caroline Robert; Jean J Grob; Daniil Stroyakovskiy; Boguslawa Karaszewska; Axel Hauschild; Evgeny Levchenko; Vanna Chiarion Sileni; Jacob Schachter; Claus Garbe; Igor Bondarenko; Helen Gogas; Mario Mandalá; John B A G Haanen; Celeste Lebbé; Andrzej Mackiewicz; Piotr Rutkowski; Paul D Nathan; Antoni Ribas; Michael A Davies; Keith T Flaherty; Paul Burgess; Monique Tan; Eduard Gasal; Maurizio Voi; Dirk Schadendorf; Georgina V Long Journal: N Engl J Med Date: 2019-06-04 Impact factor: 91.245
Authors: Grant A McArthur; Igor Puzanov; Ravi Amaravadi; Antoni Ribas; Paul Chapman; Kevin B Kim; Jeffrey A Sosman; Richard J Lee; Keith Nolop; Keith T Flaherty; Jason Callahan; Rodney J Hicks Journal: J Clin Oncol Date: 2012-03-26 Impact factor: 44.544
Authors: H Young; R Baum; U Cremerius; K Herholz; O Hoekstra; A A Lammertsma; J Pruim; P Price Journal: Eur J Cancer Date: 1999-12 Impact factor: 9.162
Authors: Helen Rizos; Alexander M Menzies; Gulietta M Pupo; Matteo S Carlino; Carina Fung; Jessica Hyman; Lauren E Haydu; Branka Mijatov; Therese M Becker; Suzanah C Boyd; Julie Howle; Robyn Saw; John F Thompson; Richard F Kefford; Richard A Scolyer; Georgina V Long Journal: Clin Cancer Res Date: 2014-01-24 Impact factor: 12.531
Authors: Matteo S Carlino; Catherine A B Saunders; Lauren E Haydu; Alexander M Menzies; C Martin Curtis; Peter F Lebowitz; Richard F Kefford; Georgina V Long Journal: Eur J Cancer Date: 2012-09-14 Impact factor: 9.162
Authors: Kerstin Trunzer; Anna C Pavlick; Lynn Schuchter; Rene Gonzalez; Grant A McArthur; Thomas E Hutson; Stergios J Moschos; Keith T Flaherty; Kevin B Kim; Jeffrey S Weber; Peter Hersey; Georgina V Long; Donald Lawrence; Patrick A Ott; Ravi K Amaravadi; Karl D Lewis; Igor Puzanov; Roger S Lo; Astrid Koehler; Mark Kockx; Olivia Spleiss; Annette Schell-Steven; Houston N Gilbert; Louise Cockey; Gideon Bollag; Richard J Lee; Andrew K Joe; Jeffrey A Sosman; Antoni Ribas Journal: J Clin Oncol Date: 2013-04-08 Impact factor: 44.544